TrialBritish journal of cancer2024

Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.

Terufumi Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.